Fasinumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | HNGF |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6406H9896N1700O2026S46 |
| Molar mass | 144618.27 g·mol−1 |
Fasinumab is a human monoclonal antibody designed for the treatment of acute sciatic pain.[1][2]
This drug was developed in collaboration by Teva Pharmaceutical Industries and Regeneron Pharmaceuticals.
It is currently at Phase III trials (NCT03245008, NCT02683239, and NCT03161093).[3]
See also
References
- ^ "Fasinumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
- ^ Tiseo PJ, Ren H, Mellis S (2014). "Fasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept study". Journal of Pain Research. 7: 523–530. doi:10.2147/JPR.S65974. PMC 4155988. PMID 25210473.
- ^ Oo WM, Hunter DJ (November 2021). "Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review". BioDrugs. 35 (6): 611–641. doi:10.1007/s40259-021-00504-8. PMID 34807432. S2CID 244509341.